Authorised by the European Medicines Agency in 2021, Skysona, the first innovative treatment for cerebral adrenoleukodystrophy (CALD), will not be marketed in Europe. The Bluebird Bio laboratory that was to produce it is closing its doors in Europe, condemning our children. Why?
RESEARCH
The only innovative treatment for CALD will not be available in Europe : the incomprehension of ELA International!